Rat and human HARE/stabilin-2 are clearance receptors for high- and low-molecular-weight heparins

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 296, Issue 6, 2009, Pages

  Harris, Edward N ^a   Baggenstoss, Bruce A ^a   Weigel, Paul H ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Biotinylated heparin; Coated pit mediated; Endocytosis; Liver sinusoidal endothelial cells; Lovenox (enoxaparin); Scavenger receptor

Indexed keywords

ENOXAPARIN; HEPARIN; PROTEIN HARE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; BIOTINYLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; ENDOCYTOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD44; BINDING, COMPETITIVE; CELL ADHESION MOLECULES, NEURONAL; CELL LINE; DEXTRAN SULFATE; ENDOCYTOSIS; ENDOTHELIAL CELLS; ENOXAPARIN; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LIGHT; LIPOPROTEINS, LDL; LIVER; MOLECULAR WEIGHT; PROTEIN BINDING; PROTEIN ISOFORMS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; SCATTERING, RADIATION; TRANSFECTION;

EID: 67049144044     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.90717.2008     Document Type: Article

References (55)

1. 51Cr-labelled heparin. Acta Physiol Acad Sci Hung 43: 261-267, 1973.
2. Baggenstoss BA, Weigel PH. Some problems associated with the use of GPC-MALLS to analyze hyaluronan size distributions made by hyaluronan synthases. In: Hyaluronan Structure, Metabolism, Biological Activities, Therapeutic Applications, edited by Balazs EA, Hascall VC. Edgewater, NJ: Matrix Biology Institute, 2005, p. 143-146.
3. Baggenstoss BA, Weigel PH. Size exclusion chromatography-multiangle laser light scattering analysis of hyaluronan size distributions made by membrane-bound hyaluronan synthase. Anal Biochem 352: 243-251, 2006.
4. Bame KJ. Heparanases: endoglycosidases that degrade heparan sulfate proteoglycans. Glycobiology 11: 91R-98R, 2001. (Pubitemid 32660349)
5. Bunting RW, Wilkinson RA, Callahan RJ, Strauss HW, Fischman AJ. Indium-111 DTPA-heparin: radiolabeling, pharmacokinetics, and biodistribution following intravenous administration in rat and rabbit. Thromb Res 89: 23-30, 1998. (Pubitemid 28231483)
6. Clarke BL, Oka JA, Weigel PH. Degradation of asialoglycoproteins mediated by the galactose receptor system in isolated rat hepatocytes. Evidence for two parallel pathways. J Biol Chem 262: 17384-17392, 1987. (Pubitemid 18032213)
7. Dawes J, Pepper DS. Human vascular endothelial cells catabolise exogenous glycosaminoglycans by a novel route. Thromb Haemost 67: 468-472, 1992.
8. Dinwoodey DL, Ansell JE. Heparins, low-molecular-weight heparins, and pentasaccharides. Clin Geriatr Med 22: 1-15, vii, 2006. (Pubitemid 41827955)
9. Estes JW, Poulin PF. Pharmacokinetics of heparin. Distribution and elimination. Thromb Diath Haemorrh 33: 26-37, 1975.
10. Fareed J, Ma Q, Florian M, Maddineni J, Iqbal O, Hoppensteadt DA, Bick RL. Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis. Semin Thromb Hemost 30, Suppl 1: 89-104, 2004. (Pubitemid 38453587)
11. Findik S, Erkan ML, Selcuk MB, Albayrak S, Atici AG, Doru F. Low-molecular-weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration 69: 440-444, 2002.
12. Fraser JRE, Laurent TC, Laurent UBG. Hyaluronan: its nature, distribution, functions and turnover. J Intern Med 242: 27-33, 1997. (Pubitemid 27323862)
13. Glimelius B, Busch C, Hook M. Binding of heparin on the surface of cultured human endothelial cells. Thromb Res 12: 773-782, 1978. (Pubitemid 8378101)
14. Guerrini M, Beccati D, Shriver Z, Naggi A, Viswanathan K, Bisio A, Capila I, Lansing JC, Guglieri S, Fraser B, Al Hakim A, Gunay NS, Zhang Z, Robinson L, Buhse L, Nasr M, Woodcock J, Langer R, Venkataraman G, Linhardt RJ, Casu B, Torri G, Sasisekharan R. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 26: 669-675, 2008. (Pubitemid 351824692)
15. Gustafson S, Bjorkman T. Circulating hyaluronan, chondroitin sulphate and dextran sulphate bind to a liver receptor that does not recognize heparin. Glycoconj J 14: 561-568, 1997. (Pubitemid 27353199)
16. Harris EN, Kyosseva SV, Weigel JA, Weigel PH. Expression, processing and glycosaminoglycan binding activity of the recombinant human 315-kDa HA receptor for endocytosis (HARE). J Biol Chem 282: 2785-2797, 2007. (Pubitemid 47084328)
17. Harris EN, Weigel JA, Weigel PH. Endocytic function, glycosaminoglycan specificity, and antibody sensitivity of the recombinant human 190 kDa HA receptor for endocytosis (HARE). J Biol Chem 279: 36201-36209, 2004. (Pubitemid 39128955)
18. Harris EN, Weigel JA, Weigel PH. The human hyaluronan receptor for endocytosis (HARE/Stabilin-2) is a systemic clearance receptor for heparin. J Biol Chem 283: 17341-17350, 2008.
19. Harris EN, Weigel PH. The ligand-binding profile of HARE: hyaluronan and chondroitin sulfates A, C, and D bind to overlapping sites distinct from the sites for heparin, acetylated low-density lipoprotein, dermatan sulfate, and CS-E. Glycobiology 18: 638-648, 2008.
20. Hiebert L. The uptake of heparin by liver sinusoidal cells in normal and atherosclerotic rabbits. Thromb Res 21: 383-390, 1981. (Pubitemid 11117037)
21. Hiebert LM, Jaques LB. The observation of heparin on endothelium after injection. Thromb Res 8: 195-204, 1976.
22. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 188S-203S, 2004. (Pubitemid 39297954)
23. Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, Lansing JC, Sriranganathan N, Zhao G, Galcheva-Gargova Z, Al Hakim A, Bailey GS, Fraser B, Roy S, Rogers-Cotrone T, Buhse L, Whary M, Fox J, Nasr M, Dal Pan GJ, Shriver Z, Langer RS, Venkataraman G, Austen KF, Woodcock J, Sasisekharan R. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 358: 2457-2467, 2008. (Pubitemid 351793019)
24. Kyosseva SV, Harris EN, Weigel PH. The hyaluronan receptor for endocytosis (HARE) mediates hyaluronan-dependent signal transduction via extracellular signal-regulated kinases (ERK). J Biol Chem 283: 15047-15055, 2008.
25. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
26. Lastoria S, Rollo HA, Yoshida WB, Giannini M, Moura R, Maffei FH. Prophylaxis of deep-vein thrombosis after lower extremity amputation: comparison of low molecular weight heparin with unfractionated heparin. Acta Cir Bras 21: 184-186, 2006. (Pubitemid 43845841)
27. Laurent TC, Fraser JRE. Hyaluronan. FASEB J 6: 2397-2404, 1992.
28. Losito R, Barlow G, Lemieux E. 3H-heparin and antithrombin III in the isolated liver perfusion. Thromb Res 10: 83-93, 1977. (Pubitemid 8035625)
29. Lynd LD, Goeree R, Crowther MA, O'Brien BJ. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma. Can J Clin Pharmacol 14: e215-e226, 2007. (Pubitemid 47324702)
30. Mahadoo J, Heibert L, Jaques LB. Vascular sequestration of heparin. Thromb Res 12: 79-90, 1978. (Pubitemid 8280128)
31. McCourt PAG, Smedsrod BH, Melkko J, Johansson S. Characterization of a hyaluronan receptor on rat sinusoidal liver endothelial cells and its functional relationship to scavenger receptors. Hepatology 30: 1276-1286, 1999. (Pubitemid 29510867)
32. McGary CT, Yannariello-Brown J, Kim DW, Stinson TC, Weigel PH. Degradation and intracellular accumulation of a residualizing hyaluronan derivative by liver endothelial cells. Hepatology 18: 1465-1476, 1993. (Pubitemid 23348438)
33. Mismetti P, Quenet S, Levine M, Merli G, Decousus H, Derobert E, Laporte S. Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis. Chest 128: 2203-2210, 2005. (Pubitemid 41507560)
34. Oie CI, Olsen R, Smedsrod B, Hansen JB. Liver sinusoidal endothelial cells are the principal site for elimination of unfractionated heparin from the circulation. Am J Physiol Gastrointest Liver Physiol 294: G520-G528, 2008. (Pubitemid 351253343)
35. Oie CI, Olsen R, Smedsrod B, Hansen JB. Liver sinusoidal endothelial cells are the principal site for elimination of unfractionated heparin from the circulation. Am J Physiol Gastrointest Liver Physiol 294: G520-G528, 2008. (Pubitemid 351253343)
36. Palm M, Mattsson C. Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. Thromb Haemost 58: 932-935, 1987. (Pubitemid 18020466)
37. Patel K, Lajoie A, Heaton S, Pianko S, Behling CA, Bylund D, Pockros PJ, Blatt LM, Conrad A, McHutchison JG. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol 18: 253-257, 2003. (Pubitemid 36513153)
38. Praaning-van Dalen DP, Brouwer A, Knook DL. Clearance capacity of rat liver Kupffer, endothelial, and parenchymal cells. Gastroenterology 81: 1036-1044, 1981. (Pubitemid 11029682)
39. Santos VN, Leite-Mor MM, Kondo M, Martins JR, Nader H, Lanzoni VP, Parise ER. Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease. Braz J Med Biol Res 38: 747-753, 2005. (Pubitemid 40867514)
40. Seglen PO. Preparation of isolated rat liver cells. In: Materials and Methods in Cell Biology, edited by Prescott DM. New York: Academic, 1976, p. 29-78.
41. Smedsrod B, Malmgren M, Ericsson J, Laurent TC. Morphological studies on endocytosis of chondroitin sulphate proteoglycan by rat liver endothelial cells. Cell Tissue Res 253: 39-45, 1988. (Pubitemid 18140095)
42. Smedsrod B, Pertoft H. Preparation of pure hepatocytes and reticuloendothelial cells in high yield from a single rat liver by means of Percoll centrifugation and selective adherence. J Leukoc Biol 38: 213-230, 1985. (Pubitemid 15243425)
43. Smedsrod B, Pertoft H, Eriksson S, Fraser JRE, Laurent TC. Studies in vitro on the uptake and degradation of sodium hyaluronate in rat liver endothelial cells. Biochem J 223: 617-626, 1984. (Pubitemid 15209054)
44. Stehle G, Wunder A, Sinn H, Schrenk HH, Friedrich EA, Dempfle CE, Maier-Borst W, Heene DL. Complexes of a modified low-molecular-weight heparin with protamine are predominantly cleared by a macrophage scavenger receptor-mediated process in rats. J Surg Res 58: 197-204, 1995.
45. Weigel JA, Raymond RC, McGary CT, Singh A, Weigel PH. A blocking antibody to the hyaluronan receptor for endocytosis (HARE) inhibits HA clearance by perfused liver. J Biol Chem 278: 9808-9812, 2003. (Pubitemid 36800482)
46. Weigel PH, McGary CT, Zhou B, Weigel JA. Purification and characterization of the hyaluronan receptor for endocytosis (HARE). In: Hyaluronan: Proceedings of an international meeting, September 2000, North East Wales Institute, UK, edited by Kennedy JF, Philips GO, and Williams PA. Abington, UK: Woodhead, 2002, p. 401-410.
47. Weigel PH, Yik JHN. Glycans as endocytosis signals: the cases of the asialoglycoprotein and hyaluronan/chondroitin sulfate receptors. Biochim Biophys Acta 1572: 341-363, 2002. (Pubitemid 35246354)
48. Williams AM, Langley PG, Osei-Hwediah J, Wendon JA, Hughes RD. Hyaluronic acid and endothelial damage due to paracetamol-induced hepatotoxicity. Liver 23: 110-115, 2003. (Pubitemid 37265782)
49. Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 67: 639-643, 1992.
50. Yuasa H, Watanabe J. Are novel scavenger-like receptors involved in the hepatic uptake of heparin? Drug Metab Pharmacokinet 18: 273-286, 2003.
51. Zammit A, Pepper DS, Dawes J. Interaction of immobilised unfractionated and LMW heparins with proteins in whole human plasma. Thromb Haemost 70: 951-958, 1993. (Pubitemid 24008806)
52. Zhou B, McGary CT, Weigel JA, Saxena A, Weigel PH. Purification and molecular identification of the human hyaluronan receptor for endocytosis. Glycobiology 13: 339-349, 2003. (Pubitemid 36592321)
53. Zhou B, Oka JA, Singh A, Weigel PH. Purification and subunit characterization of the rat liver endocytic hyaluronan receptor. J Biol Chem 274: 33831-33834, 1999. (Pubitemid 129511703)
54. Zhou B, Weigel JA, Fauss LA, Weigel PH. Identification of the hyaluronan receptor for endocytosis (HARE). J Biol Chem 275: 37733-37741, 2000. (Pubitemid 32004888)
55. Zhou B, Weigel JA, Saxena A, Weigel PH. Molecular cloning and functional expression of the rat 175-kDa hyaluronan receptor for endocytosis. Mol Biol Cell 13: 2853-2868, 2002. (Pubitemid 34907108)